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PENGESAHAN ALAT YANG DIBANGUNKAN UNTUK MENGENALPASTI 
KESERASIAN UBAT-UBAT DAN UBAT-NUTRISI PARENTERAL PADA 
NEONAT DAN PENILAIAN HASIL KLINIKAL PEMBERIAN 
 UBAT IV DAN NUTRISI PARENTERAL 
 
 ABSTRAK 
 Pemberian ubat intravena di dalam Unit Rawatan Rapi Neonatal (NICU) 
adalah kritikal kerana kesulitan akses vena, polipengubatan, penghadan cecair dan 
kadar infusi yang rendah. Apabila Nutrisi Parenteral (PN) diinfusi secara intravena, 
ini telah dianggap sebagai pembawa kepada ubat. Ubat-ubatan boleh ditambah 
kepada formulasi PN dalam usaha untuk mengurangkan keperluan cecair, 
mengurangkan keperluan suntikan tapak-Y dan mengurangkan potensi kontaminasi 
salur akibat manipulasi serta mengurangkan masa yang diperlukan untuk menyuntik 
ubat. Walau bagaimanapun, risiko tetap tinggi akibat kekurangan maklumat tentang 
keserasian fizikokimia ubatan. Kajian ini bertujuan untuk menilai hasil klinikal 
pemberian drug IV dan PN di kalangan pesakit neonat yang menerima PN semasa 
dirawat di dalam hospital dan untuk membangunkan pangkalan data tentang 
keserasian drug-drug dan drug-larutan PN.  Satu bentuk kajian Keratan Rentas 
Restrospektif telah digunapakai untuk menjalankan kajian ini. Subjek penyelidikan 
ini adalah pesakit neonat yang menerima PN di dalam Unit Rawatan Rapi Neonatal 
(NICU) Hospital Pulau Pinang, Malaysia. Subjek kajian merangkumi semua pesakit 
yang dimasukkan ke wad NICU daripada Januari 2008 hingga Disember 2009. 
Prosedur pensampelan adalah secara Pensampelan Umum dengan mengumpulkan 
semua rekod pesakit yang memenuhi kriteria kemasukan dan kriteria pengecualian 
yang ada. Sejumlah 234 bayi baru lahir yang telah memenuhi kriteria dimasukkan ke 
dalam kajian ini.  Borang pengumpulan data dihasilkan penyelidik, telah digunapakai 
xvii 
 
dan hanya seorang pemungut data yang mengumpulkan data kajian.  Kelulusan etika 
telah diperoleh dari institusi tempatan  (Jawatankuasa Penyelidikan Klinikal, CRC) 
dan daripada Jawatankuasa Etika Penyelidikan Kementerian Kesihatan (MREC). 
Data dianalisa secara statisk menggunakan  Statistic Package for Social Science 15.0 
(SPSS 15.0). Kesemua 234 (100%) pesakit yang dimasukkan ke NICU Hospital 
Pulau Pinang dimasukkan ke dalam kajian ini. Daripada jumlah ini, majoriti 123 
(52.6%) adalah perempuan dan selebihnya (47.4%) adalah lelaki. Taburan etnik 
menunjukkan Melayu mendominasi dengan 158 (67.5%) diikuti dengan Cina 41 
(17.5%), India 23 (9.8%) dan lain-lain 12 (5.1%). Kebanyakan pesakit, 98 orang 
(41.8%) telah dilahirkan pada 28-31 minggu kandungan  and 156 (66.67%) 
mempunyai berat badan di antara julat  1001-2000 gram. Ciri-ciri berkaitan pesakit 
(berat lahir, umur kandungan, mod kelahiran dan kaum-etnik) mempunyai perkaitan 
yang signifikan dengan amalan PN dan hasil klinikal. Satu pangkalan data 
dibangunkan iaitu “My. Drug Compatibility Checker (My.DCC)” yang memberikan 
maklumat keserasian berkaitan dengan interaksi drug-drug dan drug-PN bagi drug-
drug IV yang sering dipreskrib untuk pesakit NICU. Pangkalan data My.DCC adalah 
alat yang sahih dan dipercayai untuk memberikan maklumat berkaitan keserasian dan 
interaksi drug-drug di dalam bahan tambahan larutan nutrisi parenteral. Konsep, 
rekabentuk dan isi kandungan yang diperlukan untuk prototaip ini telah dikaji, 
dikumpulkan dan disediakan oleh penyelidik. Seorang juru analisa sistem terlibat 
untuk membantu membangunkan peangaturcaraan sistem. Sebanyak 29 drug 
suntikan telah dianalisa menggunakan My.DCC. Pangkalan data ini telah digunakan 
untuk menyemak keserasian daripada kombinasi rawatan ubatan yang diterima oleh 
pesakit semasa di NICU Hospital Pulau Pinang. Penemuan  My.DCC menunjukkan 
daripada 29 drug yang diberikan kepada pesakit; 4 kombinasi ubat adalah serasi di 
xviii 
 
dalam picagari,  2 kombinasi drug tidak serasi di dalam picagari, 25 kombinasi drug 
serasi dalam suntikan tapak-Y dan 8 drug tidak serasi dalam suntikan tapak-Y. Di 
kalangan pesakit, 19 neonat telah mengalami masalah keserasian interaksi drug-drug 
dan drug-nutrisi parenteral. Pengenalpastian interaksi drug-drug dan drug-nutrien 
dapat membantu ahli perubatan untuk mengelakkan komplikasi dan mencapai hasil 
yang disasarkan.  
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VALIDATION OF A DEVELOPED TOOL TO IDENTIFY COMPATIBILITY 
OF DRUG - DRUG AND DRUG - PARENTERAL NUTRITION  
IN NEONATES AND EVALUATION OF CLINICAL OUTCOME OF THE 
ADMINISTRATION OF THE IV DRUGS AND PARENTERAL NUTRITION 
 
 ABSTRACT 
 Intravenous drug administration in neonatal intensive care unit (NICU) is 
critical because of poor venous access, polymedication, ﬂuid restriction and low 
infusion rate. Since parenteral nutrition (PN) is infused intravenously, it is often 
considered as a vehicle for medication administration. Medications may be added to 
PN formulations in an effort to decrease fluid requirements, reduce the need for Y-
site injections, reduce the possibility of line contamination due to manipulation and 
decrease labor time required for drug administration. Risk is further increased by 
inadequate information on the physicochemical compatibility of drugs. This study 
aimed to evaluate clinical outcome of the administration of IV drugs and PN among 
neonates patients who had received PN during their hospitalization and to develop a 
data base on compatibility of drug-drug and drug-PN solution. A cross-sectional 
retrospective study design has been adopted to conduct this study. Subjects of this 
research were neonates’ patients receiving PN in Neonatal Intensive Care Unit 
(NICU) Hospital Pulau Pinang, Malaysia. Study subjects were all patients admitted 
in NICU from January 2008 until December 2009. Sampling procedure was 
universal sampling by collecting all available patients’ medical record that met our 
inclusion and exclusion criteria. A total of 234 newborn met the study criteria were 
included in this study. Self-developed data collection form was used with only single 
data collector for data collection. Approval for ethical clearance was obtained from 
xx 
 
the local institutions (Clinical Research Committee, CRC) and from the Ministry of 
Health Research Ethics Committee (MREC). Data was statistically analyzed using 
Statistic Package for Social Science 15.0 (SPSS 15.0). All 234 (100%) patients 
admitted to NICU Hospital Pulau Pinang were included. Among them, majority 123 
(52.6%) were females and the rest 111 (47.4) were males. Ethnic distribution showed 
predominance of Malay with 158 (67.5%) followed by Chinese 41 (17.5%), Indian 
23 (9.8%) and 12 (5.1%) others. Most of the patients; 98 (41.8%) were born at 28-31 
weeks of gestation and 156 (66.67%) were in the body weight range of 1001-2000 
grams. Patient related characteristics (birth weight, gestation age, mode of delivery 
and ethnicity) have significant association with PN practices and clinical outcomes. 
A developed database “My. Drug Compatibility Checker (My.DCC)” will provide 
the compatibility information related to drug-drug and drug-PN interaction among IV 
drugs commonly prescribed in NICU patients. Database My.DCC consider as 
validate and reliable tool to provide information regarding compatibility and drug-
drug interactions of admixture in parenteral nutrition solutions. The concept, design 
and contents required for this prototype were researched, collected and provided by 
researcher. One systems analyst was involved to carry out the programming of the 
system. The 29 injectable drugs had been analyzed with My.DCC. The database was 
used to check the possible compatibility of medication combination received during 
patient’s treatment in NICU Hospital Pulau Pinang. The My.DCC finding showed 
that among 29 drugs that administered to the patients; 4 drugs combination were 
compatible in syringe, 2 drugs combination were incompatible in syringe, 25 drugs 
combination were compatible in Y-site injection and 8 drugs were incompatible in 
Y-site injection. Among them 19 neonates had incompatible interaction of drug-drug 
and drug-parenteral nutrition interaction. Recognition of these drug-drug and drug-
xxi 
 
nutrient interactions may assist the clinician to prevent complications and to achieve 
desired therapeutics outcomes. 
 
 
1 
 
CHAPTER I 
INTRODUCTION 
 
1.1 Background 
The standard use of parenteral nutrition (PN) in clinical practice started in 1968, after 
Dudrick et al., efforts. These pioneers explained that parenteral therapy of amino acids 
and glucose concentrated solutions together with minerals, vitamins and 
micronutrients may result in more growth in children and adults. Initially PN 
admixtures were administered mostly with amino acids and glucose. Now, PN includes 
intravenous administration of amino acids, glucose, lipids, electrolytes, vitamins and 
trace elements (Dudrick, 2009, Waitzberg et al., 2006). 
 
Patients who are receiving PN often need to receive parenteral medications as well. 
Questions about parenteral drug compatibility with PN have arisen with some 
frequency (Joy et al., 2010). Unfortunately, split administration is not always feasible. 
The line being used to administer PN constantly may be the only IV access accessible 
(Mirtallo, 2004). On the other hand, even if multiple lumen catheters are used, the 
numbers of parenteral doses required in high-intensity therapeutic situations, such as 
cancer treatment or intensive care may make simultaneous administration with a PN 
admixture (Hoang et.al 2008; Kearney et.al., 1998).  
 
PN is a lifesaving medical intervention for many pediatric patients as PN provides 
energy for growth and tissue repair when the gastrointestinal tract cannot be used due 
to small stomach capacity, immature gastrointestinal tract and illnesses. This is 
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especially true for preterm or low birth weight neonates who represent the highest 
percentage of the pediatric population requiring parenteral nutrition. A small 
premature infant whose nutrition reserve are limited can survive 4-5 days if fed water 
alone and 11 days if provided with 10% dextrose alone (Brine and Ernst, 2004; Hack 
and Fanaroff, 2000; Oden and Bourgeois, 2000). 
 
PN for children is different from adults because it contains relatively more electrolytes 
and other nutrients (Iacobelli et al., 2010). Prime goals of nutritional support during 
first few days of postnatal life are, to maintain the liquid balance, to normalize 
glycaemia and to maintain levels of electrolytes and minerals in the body. In general, 
the liquid needs of large immature neonates vary from 90 to 140 mL/kg/day when they 
are in radiant warmers and 80 to 120 ml/kg/day when they are in incubators. Liquids 
are normally administered to immature neonates as 5% or 7.5% solutions of glucose, 
to avoid glycemic disorders which are common in the first days of life (Diekmann 
et.al., 2005; Falk, 1998; Jadhav et.al., 2007; Pauls et al., 1998; Ronchera-Oms et.at., 
1995). 
 
PN is one of the major advances in neonatal medicine, and it can be used successfully 
for prolonged periods in infants who cannot be fed enterally. Early use of PN can 
minimize the adverse impact of multiple metabolic complication in part because it 
provides multiple nutrients that may target a common metabolic function through 
different metabolic pathways. (NICE Guideline, 2006; Wilmore et.al, 1968). The early 
use of PN also helps to maintain an optimal nutritional states and allows the infant to 
better tolerate enteral feeding, which in turn is critical to the successful weaning of the 
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infant from PN. In contrast, inadequate nutritional support may contribute to a delay 
in growth over the short term (until hospital discharge) and over the long term by the 
persistence of growth delay into childhood, particularly in small preterm infants 
(ESPGHAN/ESPEN, 2005). 
 
The addition of medications and other additives to PN has become common practice 
in order to reduce intravenous catheter manipulations and minimizing the risk of 
contamination (Atkinson 2001; Franasois et.al., 1997; McGuire et al., 2004). Above 
all, data about micronutrient stability after adding medication to pediatric PN is almost 
rare in the literature which is vital for the welfare of the patients especially neonates 
and infants. Various issues may be related to micronutrients and macronutrients’ 
physical and chemical instability in PN together with medications (Forbes, 2004). 
 
The major obstacles encountered in delivering PN and medications in neonates are 
their limited intravenous access and fluid restriction. Fragile peripheral veins cannot 
withstand irritating chemicals in intravenous solutions and are often exhausted in a 
short period of time. The particular problem with drug therapy in infants is the 
consideration of fluid volume. Multiple drugs therapy for the acutely ill infant can 
account for a majority of the allowable fluid intake of the infant. When PN is used, the 
natural tendency is to use it as a drug delivery vehicle so as to remain within the fluid 
volume tolerance of the infant. Careful consideration must be given to the 
psychochemical properties of the drug and nutrient constituents to prevent 
incompatibilities and degradation or inactivation of certain nutrients in parenteral 
nutrition. (Niemiee et.al, 1984; Zenk et.al 1987).  
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1.2 Parenteral Nutrition in Malaysia 
Prior to early eighties, parenteral nutrition in Malaysia was provided conventionally.  
Multiple nutritional solutions were hung over the patient’s bed and administered by a 
multiple intravenous line.  The indication for PN is mainly fluid therapy rather than as 
nutritional supplement (Bahari, 1994). Parenteral nutrition in Malaysia was first 
started at the Kuantan General Hospital in 1986, followed by the Penang Hospital, 
Kuala Lumpur Hospital and Universiti Sains Malaysia Hospital (Bahari, 1994; 
Shamsuddin et.al 1994; Bahari, 1998). 
 
The role of pharmacists in the provision of PN services in Malaysian hospitals prior to 
1986 had been very minimal. In fact, their main role was limited to the procurement 
and distribution of the nutritional solutions. PN services were started in Kuantan, 
Penang and Kuala Lumpur hospitals and followed by HUSM in 1987. HUSM provided 
the PN services initially to the pediatric wards and later expanded the services to 
include adult wards especially to surgical patients.  In order to improve the role of 
pharmacists, HUSM started an Aseptic Dispensing Unit (ADU) within the Pharmacy 
Department in 1991 to provide a centralized PN service. The pharmacists from the 
ADU worked together with physicians, nurses and dietitians as a team known as TPN 
Team (Bahari, 1993). 
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1.3 Problem statement 
The neonatal period is a vital interval where nutrition can influence the infant’s growth 
and development. Failure to provide essential nutrients can result in serious conditions, 
including growth retardation, reduced respiratory and cardiac reserve, impaired 
immune system, impaired tissue and muscle functions and neurological deficits 
(Sedlacek et al., 2006; Wilson et al., 1997). The period of 30 weeks of gestational age 
to 6 months of life is vital for brain development while nutrition compromised in this 
period may cause everlasting loss of brain development. Therefore, the nutrient 
support of the preterm and critically ill infant is extremely important, not only for rapid 
endurance but also for a long-term outcome (Chaudhari and Kadam, 2006, Mermel et. 
al., 2001).  
 
Intravenous drug administration in neonatal intensive care unit (NICU) and pediatric 
intensive care units (PICU) is critical because of poor venous access, polymedication, 
ﬂuid restriction and low infusion rate. Risk is further increased by inadequate 
information on the physicochemical compatibility of drugs. Currently, no international 
guideline exists for the clinical management of drug incompatibilities. Different 
decision supporting tools such as handbooks, cross-tables and databases are available 
with essentially pertinent information about physical and chemical incompatibilities 
(De Giorgi et.al, 2010).  
 
Since PN is infused intravenously, it is often considered as a vehicle for medication 
administration. Medication may be added to PN formulations in an effort to decrease 
fluid requirements, reduce the need for Y-site injections, reduce the possibility of line 
contamination due to manipulation and decrease labor time required for drug 
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administration. Although these reasons may seem compelling, the physicochemical 
complexity of PN formulations makes their interactions with parenteral medications a 
very challenging compatibility dilemma (Mirtallo et al., 2004). 
 
Compatibility studies of medications with PN involve simulated 1:1 volume ratio 
dilutions of drug with PN admixtures, assuming the medication is administered via 
piggyback, intravenous push, or other intravenous method via the Y-site injection port 
(Driscoll, 2005). Actual concern is what happens in the tubing between the PN 
admixtures, Y-site, and venous catheter. A typical setback is an incompatibility that 
creates a precipitate or interrupts the fat emulsion stability resulting in an occluded 
catheter (Hoang et al., 2008; Kearney et.al 1998). Therefore, a drug that may appear 
to be compatible may have been altered considerably and lost most of its potency this 
way (Deshpande, 2003; Driscoll, 2003; Joy et al., 2010; Mirtallo, 2004).  
 
A major disadvantage to the use of PN solutions as drug delivery vehicles is the lack 
of compatibility and drugs interaction data in the PN solutions that are used commonly 
in clinical practice. At present no study has been performed to develop tool or data 
base on drug-drug interactions and compatibility of PN solutions commonly used by 
hospital pharmacies in Malaysia. 
 
The information necessary to address the above problem is still not available.  
Although the PN service has been introduced for more than 20 years in Malaysia, the 
data on the number of hospitals offering the service, the extend of pharmacists 
involvement, the availability of standard solution  and other related information are 
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not available in a comprehensive manner (Bahari 1999;  Shamsuddin et.al 1994; 
Bahari 1998;  Bahari 1990; Harbans 1994; Ramanujam 1994). Drug nutrient 
interaction and physicochemical compatibility of cephalosporin with parenteral 
nutrition by using HPLC have been investigated (Shahid et.al 2013). Drug-nutrient 
interactions result in derangements of fluid and electrolyte homeostasis, changes in 
vitamin status, and disturbances of the acid-base balance. Recognition of compatibility 
and these drug-nutrient interactions may assist the clinician to prevent complications 
and to achieve desired therapeutics outcomes. 
 
This study will develop and validate the database to provide compatibility information 
related to drug-drug and drug-PN interaction among IV drugs commonly prescribed 
in neonatal intensive care unit (NICU) patients in Malaysia setting. Development of 
this database is related to extend of PN practice in Malaysian Hospitals, the role of 
pharmacist and the scope of PN service. The study also will provide an evaluation of 
parenteral nutrition practice and clinical outcomes of critically ill neonates in neonatal 
intensive care unit Hospital Pulau Pinang.  
 
1.4 Objectives of the Study 
General objectives of the study were: 
1. To develop a data base to identify the compatibility of drug-drug and drug-
parenteral nutrition in NICU  
2. To evaluate current parenteral nutrition practice in Neonates at Hospital Pulau 
Pinang 
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3. To validate the developed data base as a tool to check the compatibility of the 
drug-drug and drug-parenteral nutrition in NICU patients. 
 
Specific objectives of the study were: 
1. To evaluate socio demographic characteristic, clinical complication, 
parenteral nutrition practices and clinical outcome of the neonates 
receiving parenteral nutrition and injectable drugs 
2. To identify IV drugs commonly prescribed during parenteral nutrition 
administration in neonate patients 
3. To evaluate compatibility and clinical outcome of the neonates receiving 
parenteral nutrition and injectable drugs 
4. To develop a database to identify the compatibility of drug-drug and drug-
PN in NICU patients. 
 
 
1.5 Hypothesis of the study 
Hypothesis of the study was: 
Ho: There is no association of clinical condition among neonates receiving parenteral 
nutrition and injectable drugs with the compatibility of drug-drug and drug-parenteral 
nutrition interaction. 
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1.6 Significance of the study  
1. The study will contribute in the improvement of quality of nutritional care of 
neonatal intensive care patients by reducing the risks of drug-drug and drug-nutrient 
interactions of PN formulation. 
2. The databases can be used to develop guideline in prevention of drug-drug or drug-
parenteral nutrition interactions. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Nutritional support 
2.1.1 Oral nutrition 
Oral supplements should be prescribed for those unable to meet their nutritional 
requirements from the hospital menu. These supplements are available in a variety of 
flavours such as in semi-solid or powder form, as well as cartons of liquid. Verbal 
encouragement, offering a mix of flavours and giving them chilled or as a milkshake 
aids compliance (ASPEN 2002). 
 
2.1.2 Enteral Nutrition 
All people need food to live, however sometimes a person cannot eat any or enough 
food because of an illness while others may have a decreased appetite, difficulties in 
swallowing, or some types of surgery that interferes with eating. When this occurs, 
and one is unable to eat, nutrition must be supplied in a different way. One method is 
“enteral nutrition” often called “tube feeding”. Tube feeding is a method in which a 
special liquid food formula containing protein, carbohydrates (sugar), fats, vitamins 
and minerals, is given through a tube into the stomach or small bowel. People of all 
ages have received tube feeding. It may be given to infants and children, as well as to 
adults. Tube feeding can be used for a short time, and then the tube is removed when 
the person can begin to eat normally again. Tube feeding can be given through 
different types of tubes. One type of tube can be placed through the nose into the 
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stomach or small bowel. This tube is called a nasogastric or nasoenteral feeding tube. 
Sometimes the tube is placed directly through the skin into the stomach or small bowel. 
This method is called a gastrostomy or jejunostomy (ASPEN 2002; ASPEN 2009). 
 
If the patient is unable (e.g. nausea, frailty) to drink nutritional sip feeds, enteral tube 
feeding should be considered. The benefits of enteral tube feeding include: nutrients 
are effectively mobilized and utilized as compared to parenteral feeding, function of 
the gut barrier is preserved, preventing ‘bacterial translocation’ can be prevented, 
hence reducing the chance of sepsis, complications are generally less serious than 
those of parenteral nutrition, and it is also cheaper and easier to manage than parenteral 
nutrition. Choice of enteral tube feeds depends on: the route of nutritional support, 
nutritional requirements, impairment of the gastrointestinal tract and associated 
clinical conditions (e.g. renal or liver failure) (Merce et.al, 2002). 
 
2.1.3 Parenteral Nutrition 
Parenteral nutrition (PN) is intravenous administration of nutrition, which may include 
protein, carbohydrate, fat, minerals and electrolytes, vitamins and other trace elements 
for patients who cannot eat or absorb enough food through tube feeding formula to 
maintain good nutrition status. Achieving the right nutritional intake in a timely 
manner can help combat complications and be an important part of a patient’s recovery 
(ASPEN 2009). 
 
Parenteral nutrition is sometimes called Total Parenteral Nutrition (PN). People of all 
ages also receive parenteral nutrition. Like tube feeding, it may be given to infants and 
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children, as well as to adults. People can live well on parenteral nutrition for as long 
as it is needed. Many times, parenteral nutrition is used for a short time; then it is 
lessened or discontinued when the person begins to eat normally again. Parenteral 
nutrition bypasses the normal digestion in the gastrointestinal (GI) tract. It is a sterile 
liquid chemical formula given directly into the bloodstream through an intravenous 
(IV) catheter (needle in the vein). Patients may need PN for any variety of diseases or 
conditions that impair food intake, nutrient digestion or absorption. Some diseases and 
conditions where PN is indicated include but are not limited to short bowel syndrome, 
GI fistulas, bowel obstruction, critically ill patients, and severe acute pancreatitis. 
Some patients may require this therapy for a short time and there are other patients 
who have received TPN at home for a lifetime. PN is a life-saving yet complex therapy, 
which is not without risk of complications. Some of these complications include 
infection, metabolic, and fluid issues. Management by an interdisciplinary Nutrition 
Support Team can optimize patient outcomes associated with this therapy (ASPEN 
2009; JPEN 2004). 
 
Failure of enteral feeding is the main indication for parenteral nutrition. Enteral tube 
feeding is inappropriate in proximal intestinal fistulas, intestinal obstruction or post-
chemotherapy mucositis. Total intravenous feeding is commonly used. Long-term 
parenteral nutrition is well established and can be delivered at home safely and with 
an excellent quality of life (JPEN, 2004) 
  
2.1.4 Parenteral Nutrition in Adult 
Parenteral nutrition refers to TPN formulations; total nutrient admixtures (TNA) are 
TPN formulations that include intravenous fat emulsion (IVFE); and 2 in 1 
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formulations are TPN formulations that do not include IVFE. PN formulations are 
extremely complex admixtures containing 40 or more components including both 
macronutrients (carbohydrates, lipids, amino acids) and micronutrients (electrolytes, 
trace minerals and vitamins).  These nutrients are mixed into a bag and infused 
simultaneously into the blood circulation through the peripheral or central vein. 
(Maisonneuve et.al, 2004; Mirtallo et.al 2004). 
 
PN is indicated in patients with a non-functioning digestive tract to correct or maintain 
their nutritional status. They can be administered in any of the following ways: firstly, 
the classic separate bottles (SB) system in which nutrients are stored in separate bottles 
or bags and infused through separate intravenous (IV) lines. This system requires 
numerous IV line manipulations and is associated with increased risk of administration 
errors, as well as septic and metabolic complications. Secondly, the ‘all-in-one’ system 
in which all nutrients are mixed in one bag and infused simultaneously. This system 
requires only one IV line, thus decreasing manipulation-related and metabolic risks. 
Thirdly, three-compartment bags containing macronutrients and electrolytes in three 
separate compartments. Nutrients are mixed just prior to infusion, by breaking the 
plastic connectors between the compartments, and then vitamins and trace elements 
are added extemporaneously to the bag. The shelf-life of these bags is at least 12 
months, but it is only useful for standardized formulas. PN provides life-sustaining 
therapy for patients who are unable to consume conventional dietary therapy either 
orally or enterally (Maisonneuve et.al 2004; Riyadh et.al, 2007). 
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Nowadays, the term PN is widely used in the literature to denote the administration of 
nutrients intravenously. Basically, PN is only indicated when the oral, or enteral, route 
of nutrition cannot be established (i.e. the use of the gastrointestinal system), or is 
insufficient for the maintenance of the patient’s nutritional requirements in relation to 
his/her clinical status. Partial parenteral nutrition is the concurrent IV administration 
of nutrients together with oral or enteral nutrition for the same therapeutic objective. 
The dietary components of a standard PN regimen are the macronutrients (protein or 
amino acids, carbohydrates and fats), the electrolytes, the micronutrients (trace 
elements and vitamins) and water. Carbohydrates, in the form of glucose or dextrose, 
and lipids are the major sources of energy (Shamsuddin et.al, 2003). 
 
2.1.5 Parenteral Nutrition in Pediatric 
PN is used to treat children that cannot be fully fed by oral or enteral route, for example 
due to severe intestinal failure (Wilmore et.al, 1968). Intestinal failure occurs when 
the gastrointestinal tract is unable to ingest, digest and absorbs sufficient 
macronutrients and/or water and electrolytes to maintain health and growth. Children 
differ from adults in that their food intake must provide sufficient nutrients not only 
for the maintenance of body tissues but also for growth. This is particularly true in 
infancy and during adolescence when children grow extremely rapidly. At these times 
children are particularly sensitive to energy restriction because of high basal and 
anabolic requirements (Heird et.al 1972; Koletzko et.al, 2005). 
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The ability to provide sufficient nutrients parenterally to sustain growth in infants and 
children suffering from intestinal failure or severe functional intestinal immaturity 
represents one of the most important therapeutic advances in pediatrics over the last 
three decades. Improvements in techniques for artificial nutritional support now ensure 
that children in whom digestion and absorption are inadequate or who are unable to 
eat normally no longer need to suffer from the serious consequences of malnutrition 
including death. (Tsang et.al 2005; Royal College of Pediatrics and Child Health, 
1997). 
 
2.1.6 Parenteral Nutrition in Neonates  
Total parenteral nutrition (PN) is the intravenous infusion of all nutrients necessary for 
metabolic requirements and growth. PN refers to the supplemental intravenous 
infusion of nutrients by peripheral or central vein. Enteral nutrition (EN) is provided 
by oral or gavage feedings. PN is commonly indicated in neonates experiencing 
congenital malformation of the gastrointestinal tract, gastroschisis, meconium and 
paralytic ileus, short bowel syndrome, necrotizing enterocolitis (NEC), respiratory 
distress syndrome, extreme prematurity, sepsis, and malabsorption. The ability to 
provide PN over the past four decades has significantly improved the overall survival 
of newborns when other options of adequate nutritional support were not possible 
(Brine et.al, 2004). 
 
The goal of PN is to initially provide sufficient nutrients to prevent negative energy 
and nitrogen balance and essential fatty acid deficiency and support normal rates of 
intrauterine growth of appropriate composition without increased significant 
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morbidity. Fear of toxicity and metabolic imbalance has alerted clinicians to use PN 
with caution, especially in the sickest and most premature infants. An increasing 
number of practitioners appreciate that this cautionary management has resulted in 
suboptimal nutrition intake of these infants. Practitioners have speculated that this 
cautionary practice contributed in part to national growth failure outcome statistics 
published of infants extremely low in birth weight (ELBW; less than 1,000 grams) and 
appropriate for gestational age (AGA; weight ≥10th percentile norm) born from 1995 
to 1996. When assessed at discharge (≈ 36 weeks’ corrected age) 99% of these infants 
had significant growth failure with weights less than the 10th percentile compared with 
intrauterine growth standards.(Brine et.al 2004; Lemons et.al 2001) Longer-term 
statistics indicate that a significant percentage of infants born very low in birth weight 
(VLBW; less than 1,500 grams) may suffer substantial neurodevelopmental deficits in 
part attributable to inadequate nutritional support in the neonatal period.(Hack et.al, 
1999) In more recent years, the earlier introduction and more aggressive advancement 
of TPN was shown to be safe and effective, even in the smallest and most immature 
infants (Thureen et.al 1999; Thureen et.al, 2000; Thureen et.al 2003, Heird et.al 1999, 
Poindexter et.al 2003). 
 
Timely intervention with PN begins with the provision of glucose as soon as possible 
after birth with amino acids within the first 12 hours, intravenous fat within the first 
24 to 48 hours, and trophic feeding within the first 24 hours. (Wilson et.al 1997). 
Optimal use of routine PN for nutritional support of ELBW and VLBW infants may 
influence short-term outcomes such as lower propensity to infection and shortened 
hospital stay, as well as longer-term outcomes such as decreased growth deficits 
improved neurodevelopment, and overall morbidity (Hay et.al 1999; Dusick et.al, 
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1998; Vohr et .al, 2000). Indications that are generally recognized as those that 
necessitate PN for newborns are listed in Table 2.1.  
Table 2.1 Indications for PN Support and Route of Administration for Neonates 
Who Require Intensive Care (adapted from Brine E and Ernst J (2004), Newborn 
and Infant Nursing Reviews, 4, 133-155.) 
Route of PN Administration Indication for PN 
Peripheral    
 
 
 
 
 
 
Central 
Temporary supply of nutrients <2 weeks: 
- Less Enteral intake 
- Functional gut immaturity 
- Temporary feeding intolerance 
- Medical instability 
 
Prolonged nonuse of the gastrointestinal 
(GI) tract >2 weeks: 
- Short bowel syndrome 
- Surgical GI disorders 
- Necrotizing enterocolitis 
- Intractable diarrhea 
- Meconium ileus 
- Line access in infants extremely low 
in birth weight <1,000 grams 
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2.1.7 Components of PN Solutions 
PN provides some or all nutrients of basal metabolism and growth for fluid, energy, 
macronutrients(protein, carbohydrate, and fat) and micronutrients (electrolytes, major 
minerals, trace minerals, and vitamins) (Price et.al 2000; Anderson et.al 2000; Ziegler 
et.al 1976; Peter 1997; Yardley 1992; Vileisis 1987; Schanler 2003; Krug 2000). 
Recommended intakes for premature and term neonates are summarized in Table 2.2: 
 
Table 2.2 Usual Daily Requirements of Nutrients in PN Solutions for Preterm and 
Term Neonates (adapted from Brine E and Ernst J (2004), Newborn and Infant 
Nursing Reviews, 4, 133-155.) 
Nutrient Additive Usual Daily requirements in PN 
Neonatal amino acid    
 
 
 
 
 
 
 
 
 
 
Cysteine hydrochloride 
 
 
 
Dextrose 
 
 
 
 
For maintenance:    
1.5-2.5 g/kg/d 
For ELBW infants, begin at a minimum of 1.5 g/kg/d as soon 
as possible.     
Goals for growth: 
3.5 g/kg/d for  <1,000 grams 
3.0 g/kg/d for  1,000-2,500 grams 
2.5 g/kg/d for  >2,500 g 
4.0 g/kg/d for some infants with 
greater needs 
 
40 mg/g of amino acids (120 mg/kg maximum) 
Refer to acetate guidelines for ELBW infants (see below 
under Excess anions) 
 
For maintenance: 
4-6 mg/kg/min (endogenous hepatic glucose 
production) 
8-10 mg/kg/min (preserves carbohydrate stores) 
Goals for growth: 12-13 mg/kg/min 
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Lipid (20% emulsion from 
100% soy oil) 
 
 
 
 
 
Energy 
 
 
 
 
 
 
Carnitine 
 
Heparin 
 
 
 
Sodium (Na) as chloride or 
Phosphate 
 
 
 
Potassium (K) as chloride 
or phosphate 
 
 
 
Chloride (Cl) 
 
 
Excess anions 
      Acetate 
      Chloride 
Usual maximum concentration: 
12.5% peripheral route 
20-25% central route 
 
0.5-4.0 g/kg/d; Begin 0.5-1.0 g/kg/d and advance by 0.5-1.0 
g/kg/d 
Essential fatty acids met with 1.0 g/kg/d and at least 80 
kcal/kg/d 
Delivered as a component to the amino acid–glucose solution 
(admixture) or as a separate solution 
 
Goals for maintenance 
Preterm/term: 60 kcal/kg/d 
Goals for growth 
Preterm: 90-110 kcal/kg/d 
Term: 80-90 kcal/kg/d 
Dextrose (40-60%), lipid (40-50%), protein (10-15%) 
 
2-10 mg/kg/d not to exceed 50 mg/kg/d 
 
1 unit/mL not to exceed 137 units/d 
0.5 unit/mL for ELBW infants when volume exceeds 150 
mL/kg/d 
 
2-4 mEq/kg/d 
Positive nitrogen balance is critical 
for growth; ELBW infants may 
require increased intake 
 
2-4 mEq/kg/d 
Consider omitting in ELBW infants 
until renal sufficiency is well 
established 
 
2-4 mEq/kg/d 
Usual Na:Cl is 1:1 
 
Excess anion equivalent = (Na+ K) - (Cl+ P) 
 Usually provide electrolytes as acetate Always use acetate if 
adding cysteine hydrochloride for ELBW 
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Calcium (Ca) as gluconate 
 
 
 
 
Phosphorus (P) as sodium 
or potassium phosphate 
 
Magnesium (Mg) 
 
 
 
 
Vitamins as MVI-Pediatric 
 
 
Zinc (Zn) as sulfate or in pediatric 
trace element  (PTE) solution 
 
 
 
 
Copper (as sulfate or in PTE) 
 
 
 
 
Selenium in PTE 
 
 
 
 
 
 
Chromium in PTE 
 
 
 
 
 
1-3 mEq/kg/d for maintenance 
3-4.5 mEq/kg/d for growth (see text for solubility limits) 
Should be administered through a central line rather than a 
peripheral line in premature infants 
 
1.3 mmol/kg/d for maintenance 
1.5-2.0 mmol/kg/d for growth   
 
0.25-1.0 mEq/kg/d 
Begin ELBW infants at low end       
Increased needs for infants with 
ostomy losses 
 
Premature: 2 ml/kg/day to a maximum of 5 mL/d 
Term: 5 mL/d            
 
400µg/kg/d: Preterm infants and all infants with 
gastrointestinal losses 
250µg/kg/d: Term infants 0-3 months 
100µg/kg/d: Term infants > 3 months and all infants with 
long-term TPN 
 
Withhold during the first 2 weeks of TPN, then initiate at 20 
µg/kg/day 
Decrease amount or withhold with complication of 
obstructive jaundice 
 
Withhold during the first 2 weeks of TPN 
Decrease amount or withhold with complication of renal 
dysfunction 
Premature: Begin at 1.3 µg/kg/d and advance to 1.5-2.0 
µg/kg/d 
Term: 2.0 µg/kg/d 
 
Withhold during the first 2 weeks of TPN 
Decrease amount or withhold with complication of renal 
dysfunction 
Premature: Begin at 0.05µg/kg/d and advance to 0.05-0.2 
µg/kg/d 
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Manganese in PTE 
 
 
 
 
 
Iodide (I) 
 
 
Molybdenum (Mb) 
 
 
 
 
Iron (Fe) as dextran or ferrous 
citrate 
 
 
 
Fluoride (Fl) 
 
 
Term: 0.2 µg/kg/d 
 
Withhold during the first 2 weeks of TPN 
Decrease amount or withhold with complication of 
obstructive jaundice 
Premature: Begin at 0.75 µg/kg/d and advance to 1.0 µg/kg/d 
Term: 1.0 µg/kg/d 
 
Withhold for the first 3 months of TPN 
Premature: 1.0µg/kg/d 
 
Withhold for the first 3 months of TPN 
Decrease amount or withhold with complication of renal 
dysfunction 
Premature/term: 0.25µg/d 
 
May withhold until 2 months of age (Premature), 3 months of 
age (Term) and considered for infants who do not receive 
regular blood transfusions. 
Premature/Term: 1.0-2.0µg/kg/d 
 
Withhold for the first 3 months of TPN then provide premature 
with 500µg/kg/d 
Solutions may be contaminated with fluoride           
 
Zinc is unanimously suggested from day one of PN therapy, while the rest trace 
minerals are commonly administered after three, five, or twelve weeks of PN without 
any significant enteral feeding (Hardy et al., 2001). Zinc requirements are increased in 
metabolic stress secondary to increased urinary losses and in gastrointestinal disease 
secondary to ostomy or diarrheal losses. ELBW infants need additional zinc than term 
infants (Pluhator-Murton et al., 1999). Selenium stores have been revealed to be 
depleted in patients receiving long-term parenteral nutrition or in those with thermal 
injury, acquired immunodeficiency syndrome, or liver failure. Therefore, selenium 
should be added initially to the parenteral nutrition solution for patients with these 
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disease states or conditions (Dworkin, 1994; Hardy et al., 2001; Hunt et al., 1984; 
Pluhator-Murton et al., 1999). Recommended intravenous intake of trace elements for 
neonates and infants has been shown in Table 2.2.  
 
Parenteral iron supplementation may be delayed until two months of age in premature 
infants and three months of age in term infants but it can be considered for those infants 
who do not receive regular blood transfusions. Supplementation of iodide in PN may 
not be necessary because iodide needs may be met by other routine usages of topical 
iodide-containing disinfectants, detergents and other environmental sources (Al-Saleh 
et al., 2005; Baptista et al., 1984; Blazewicz et al., 2010; Ekin et al., 2003; Leung, 
1995; Leung, 1998; Leung et al., 1995; Ono et al., 1995; Papageorgiou et al., 2002; 
Rahman et al., 2009; Yanik et al., 2004) 
 
2.1.7 (a). Fluid 
On day one of life, maintenance of fluids are met with arrangement between 80 and 
140 mL/kg/d if the environment of the baby increases insensible water losses and 60 
to 100mL/kg/d in environments with increased humidity. Thereafter, fluid volume is 
advanced as tolerated to 120 to180 mL/kg/d. Maximal fluid volume varies with 
individual management (Anderson 2000). 
 
2.1.7 (b). Macronutrients 
Carbohydrate (dextrose) and fat (lipid emulsions) provide the energy needed to meet 
the demands of the circulatory, respiratory, neurological, and muscular systems and, 
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when provided in adequate amounts, spare protein(amino acids) to support cell 
maturation, remodeling, growth, activity of enzymes, and transport proteins for all 
body organs. Energy needs may be increased with infection, chronic lung disease, 
healing, growth, and in neonates who have experienced intrauterine growth restriction 
(IUGR). Energy needs may be decreased with sedation, mechanical ventilation, and 
after tracheotomy placement. 
 
The use of PN is suggested to support all ill and premature neonates less than 1,500 
grams that cannot sustain at least ~60 kcal/kg/d enterally and initiation 
isrecommended during the first 24 hours of life to avoidexcessive protein losses. The 
premature infant who is not growing, not septic, and not unduly stressed requires an 
energy intake of about 50 kcal/kg/d for resting energy expenditure, activity, and 
occasional cold stress, (Denne et.al 2002; Leitch et.al 2000; Zlotkin et.al 1981; Bell 
1996) with as little as ~1 to 1.5 g protein/kg/d to preserve endogenousprotein stores 
(Thureen et.al 2003; Ziegler 1994; Thureen et.al 1998). At least 60 kcal/kg/d is thought 
to meet energy requirements during acute sepsis (Premer et.al 1999). 
 
(i). Carbohydrate 
Carbohydrate is delivered in 2.5 to 70% dextrose solutions that provide 3.4 kcal/g. 
Glucose is the energy source for all cells and is essential for the central nervous system 
(CNS), erythrocytes, and other tissues. To ensure a stressed premature infant receives 
an adequate but not excessive amount of glucose, the amount of carbohydrate 
delivered in the form of dextrose is commonly initiated at the endogenous hepatic 
glucose production and utilization rate of 4 to 6 mg/kg/min (Denne et.al 1986) 8 to 10 
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mg/kg/min in ELBW infants provides 40 to 50kcal/kg/d and preserves carbohydrate 
stores (Hertz et.al 1993). 
 
Frequently smaller, more unstable premature infants develop hyperglycemia due to 
decreased insulin production and insulin resistance. Glucose infusion rates (GIR) for 
these neonates may need to be limited to 4 mg/kg/min or less, while larger preterm 
infants or term infants can often tolerate up to 8 mg/kg/min initially (Denne et.al 2002; 
Lifshitz 1988). Once the GIR supports acceptable serum glucose values, it is advanced 
in a gradual, stepwise fashion (0.5 to 1 mg/kg/min) to a suggested maximum glucose 
oxidative rate for neonates of 12 to 13 mg/kg/min to support growth and maintained 
there unless serum glucose values change significantly (Reiter et.al 2001; Baker et.al 
1997). 
 
In most situations, a glucose concentration above12.5% is not necessary (Denne et.al 
2002). However a higher glucose concentration may be needed when fluid intake is 
severely restricted or when the amounts of protein and/or fat are limited (Denne et.al 
2002). Excessive carbohydrate delivery above the amount that can be oxidized for 
energy and glycogen storage will lead to an increase in basal metabolic rate (Kanarek 
et.al 1991) fat deposition, cholestasis (Henry, 2003), hepatic steatosis (Shulman 2000) 
or over feeding as described by the provision of energy in excess of needs for normal 
growth (Shulman 2000). GIR greater than 26 mg glucose/kg/min may contribute to 
infiltrates of fat in the liver (Pediatric Nutrition Handbook 2004). 
 
